US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

10.85

-0.2400-2.16%

Post-market: 10.900.0500+0.46%19:30 EDT

Volume:186.29K

Turnover:2.03M

Market Cap:3.68B

PE:113.75

High:10.96

Open:10.94

Low:10.80

Close:11.09

52wk High:12.48

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:1.85

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0954

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.54

PE(LYR):-514.22

Loading ...

Overview Company News Filings

Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?

Simply Wall St.

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates

Simply Wall St.

Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?

Simply Wall St.

Telix Pharmaceuticals Says Citigroup Lifts Stake

MT Newswires Live

Telix Issues New Deferred Share Rights Under Employee Incentive Scheme

UBS Remains a Buy on Telix Pharmaceuticals (TLPPF)

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)

Telix Resubmits U.S. FDA Application for Glioma Imaging Agent TLX101-Px

A Look At Telix Pharmaceuticals’ Valuation After ProstACT Global Phase 3 TLX591-Tx Milestone

Simply Wall St.

Telix Pharmaceuticals (ASX:TLX) Is Up 11.3% After Positive Phase 3 TLX591-Tx Safety Data - What's Changed

Simply Wall St.

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix Tightens Capital Structure as Incentive Rights Lapse and Are Cancelled

Telix Seeks ASX Quotation for New Employee Share Plan Securities

UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Why Is Telix Pharmaceuticals Stock Gaining Tuesday?

Benzinga_recent_news

Telix Says Part 1 of Late-Stage Trial of Prostate Cancer Treatment Achieves Primary Objectives

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/TLX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":10.85,"timestamp":1788292800000,"preClose":11.09,"halted":0,"volume":186285,"hourTrading":{"tag":"盘后","latestPrice":10.9,"preClose":10.85,"latestTime":"19:30 EDT","volume":307,"amount":3377.89,"timestamp":1788305401094,"change":0.05,"changeRate":0.004608,"amplitude":0.019355},"delay":0,"changeRate":-0.021641118124436448,"floatShares":272000000,"shares":339000000,"eps":0.095386,"marketStatus":"Closed","change":-0.24,"latestTime":"09-01 16:00:00 EDT","open":10.94,"high":10.96,"low":10.8,"amount":2025172.974165,"amplitude":0.014427,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.095386,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":11.09,"preHourTrading":{"tag":"盘前","latestPrice":10.93,"preClose":11.09,"latestTime":"09:29 EDT","volume":3089,"amount":33870.066415,"timestamp":1788269341007,"change":-0.16,"changeRate":-0.014427,"amplitude":0.004509},"postHourTrading":{"tag":"盘后","latestPrice":10.9,"preClose":10.85,"latestTime":"19:30 EDT","volume":307,"amount":3377.89,"timestamp":1788305401094,"change":0.05,"changeRate":0.004608,"amplitude":0.019355},"volumeRatio":1.85032},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":1.85032,"shares":339000000,"dividePrice":0,"high":10.96,"amplitude":0.014427,"preClose":11.09,"low":10.8,"week52Low":6.28,"pbRate":"7.54","psRate":"4.13","week52High":12.48,"institutionHeld":0,"latestPrice":10.85,"eps":0.095386,"divideRate":0,"volume":186285,"delay":0,"ttmEps":0.095386,"open":10.94,"prevYearClose":7.49,"prevWeekClose":11.29,"prevMonthClose":11.09,"prevQuarterClose":11.53,"fiveDayClose":11.69,"twentyDayClose":10.29,"sixtyDayClose":9.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-08-31","current":113.748349,"percent":0.277405,"low":-584.49693,"twenty":-444.681415,"median":171.697901,"eighty":244.624606,"high":383.853933,"avg":23.216454,"sd":312.762668,"marketCap":3737797575.74},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96},{"date":"2026-08-28","current":114.191675,"twenty":-444.681415,"median":171.69944,"eighty":244.665977,"marketCap":3825078550.57},{"date":"2026-08-31","current":111.58604,"twenty":-444.681415,"median":171.697901,"eighty":244.624606,"marketCap":3737797575.74}],"updateTime":1788310945528},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624652093","title":"Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652093","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624652093?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:39","pubTimestamp":1775108345,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Citigroup Global Markets Australia and related Citi group entities have notified Te...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/citi-group-entities-exit-substantial-holder-status-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/citi-group-entities-exit-substantial-holder-status-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BSNM7G36.USD","BK4534","LU2462157665.USD","LU0980610538.SGD","LU0106831901.USD","LU2125154778.USD","LU1201861249.SGD","LU0162691827.USD","BK4559","BK4585","LU0098860793.USD","LU1244550494.USD","LU1366192091.USD","LU0310800965.SGD","LU1668664300.SGD","LU1244550577.SGD","LU2125154935.USD","BK4207","LU0130517989.USD","LU1791807156.HKD","LU0072461881.USD","BK4566","LU0648001328.SGD","BK4504","LU0128525689.USD","LU2456880835.USD","BK4139","LU0477156953.USD","LU0130102774.USD","LU2236285917.USD","LU1162221912.USD","LU1506573853.SGD","LU0052756011.USD","LU2360032135.SGD","TLX","LU2417539215.USD","LU1244550221.USD","BK4588","LU0314106906.USD","LU0170899867.USD","LU0320765646.SGD","LU1267930227.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547779","title":"Telix Appoints David Gill as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547779","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547779?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:59","pubTimestamp":1775084340,"startTime":"0","endTime":"0","summary":"Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoiceHoldings, Inc. , INC Research , and CTI Molecular Imaging . He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.Telix Interim Chair, Mark Nelson, commented, \"We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.\". Telix Investor Relations Ms. Charlene JawAssociate Director Investor Relations[emailprotected]","market":"us","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-appoints-david-gill-as-non-executive-director-302732101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK7067","TQQQ","QYLG","NQmain","YMAB","BK4139","INCR","NDX","QLD","QQQE","QQQY","BK4007","TLX","TLX.AU","EOLS","BK4526","QQQ","SBBP","QDTE","ASX","MNQmain","JEPQ","SQQQ","NVIW.SI","QID","FTEC","BK4141","BK7039","ASX.AU","PSQ","QQQJ","QQQM","SEC.AU","IYW",".IXIC","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622809302","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622809302","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622809302?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:14","pubTimestamp":1774653245,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment effects in adult and pediatric patients, incorporating additional data and analysis requested after a prior Complete Response Letter.\nThe filing is significant because TLX101-Px holds both Orphan Drug and Fast Track designations and could become the first FDA-approved...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","BK7067","TLX.AU","LABU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4108","AEM.AU","TOR.AU","FEX.AU","BK4505","REG.AU","BK7017","BK7007","BK7113","AV1.AU","BK7110","BK7067","CUV.AU","TLX","BK4139","BK7104","BK4531","IQ","BK7129","BK4552","AR1.AU","FRS.AU","CYC.AU","BK7095","EIQ.AU","BK7016","BK4526","TLX.AU","BK7508","MAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621507720","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621507720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621507720?lang=en_us&edition=fundamental","pubTime":"2026-03-23 12:27","pubTimestamp":1774240038,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has entered a busy regulatory phase, resubmitting its TLX101-Px New Drug Application for glioma imaging while also reporting that the lead-in stage of its TLX591-Tx Phase 3 prostate cancer trial met safety objectives.\nSee our latest analysis for Telix Pharmaceuticals.\nThese regulatory updates come after a strong short term run, with a 1 month share price return of 22.24% and a 7 day share price return of 12.93%. However, the 1 year total shareholder return is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621183756","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621183756","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621183756?lang=en_us&edition=fundamental","pubTime":"2026-03-21 01:13","pubTimestamp":1774026782,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment-related changes in adults and children, incorporating additional data requested after a prior Complete Response Letter and supported by Orphan Drug and Fast Track designations.\nA key differentiator is that 18F-FET imaging like TLX101-Px is already referenced in international glioma...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BGSX","BK7067","TLX.AU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620202561","title":"Telix Pharmaceuticals Says Citigroup Lifts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620202561","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620202561?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:17","pubTimestamp":1773983826,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) received notice that Citigroup and its affiliates increased their holdings in the company to 6.0668% from 5.0639%, according to a Friday filing with the Australian bourse.Citigroup and its affiliates now own 20.6 million shares in the company, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","TLX","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620327449","title":"Telix Issues New Deferred Share Rights Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2620327449","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620327449?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:53","pubTimestamp":1773957200,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals has notified the market of the issue of 126,668 new unquoted securi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-deferred-share-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-deferred-share-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291040","title":"UBS Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291040?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:35","pubTimestamp":1773880555,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$31.00. According to TipRanks, Dai is a 3-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UBS","LU1829250122.USD","BK4585","LU1863844749.USD","BK4534","LU3187612489.SGD","BK4118","TLPPF","BK4139","TLX","BK4588","LU1863844665.USD","IE0034235071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619648928","title":"Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619648928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619648928?lang=en_us&edition=fundamental","pubTime":"2026-03-16 07:30","pubTimestamp":1773617411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apogee Therapeutics (APGE – Research Report), Wave L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apogee-therapeutics-apge-wave-life-sciences-wve-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apogee-therapeutics-apge-wave-life-sciences-wve-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4585","LU0128526141.USD","LU0029874061.USD","APGE","BK4007","TLX","WVE","BK4139","LABU","XBI","BK4581","XLV","BK4588","LU0053671581.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619863514","title":"Telix Resubmits U.S. FDA Application for Glioma Imaging Agent TLX101-Px","url":"https://stock-news.laohu8.com/highlight/detail?id=2619863514","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619863514?lang=en_us&edition=fundamental","pubTime":"2026-03-16 06:08","pubTimestamp":1773612488,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has resubmitted a New Drug Application to the U.S. FDA for TL...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-resubmits-u-s-fda-application-for-glioma-imaging-agent-tlx101-px?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-resubmits-u-s-fda-application-for-glioma-imaging-agent-tlx101-px?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4585","LABU","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619170812","title":"A Look At Telix Pharmaceuticals’ Valuation After ProstACT Global Phase 3 TLX591-Tx Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170812","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619170812?lang=en_us&edition=fundamental","pubTime":"2026-03-15 11:34","pubTimestamp":1773545683,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after announcing that Part 1 of its ProstACT Global Phase 3 trial for TLX591-Tx met key safety and tolerability endpoints, clearing the way for the study's expansion.\nSee our latest analysis for Telix Pharmaceuticals.\nThe ProstACT Global update comes after a strong 30 day share price return of 24.34% and a 7 day share price return of 5.02%. However, the 1 year total shareholder return shows a decline of 58.55% and the year to date share price...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-after-prostact-glo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-after-prostact-glo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USD","TLX.AU","BK7067","BK4139","USD.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619474195","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 11.3% After Positive Phase 3 TLX591-Tx Safety Data - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2619474195","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619474195?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:36","pubTimestamp":1773383783,"startTime":"0","endTime":"0","summary":"In early March 2026, Telix Pharmaceuticals reported that Part 1 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer met its primary safety and dosimetry objectives, with an acceptable tolerability profile and no new safety signals across combinations with standard-of-care therapies.\nA distinctive aspect for investors is that TLX591-Tx’s antibody-based design showed minimal kidney, salivary and lacrimal gland exposure versus existing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-113-after-positive-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-113-after-positive-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618397415","title":"Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618397415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618397415?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:15","pubTimestamp":1773270920,"startTime":"0","endTime":"0","summary":"In a report released today, John Hester from Bell Potter maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$19.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618681971","title":"Telix Tightens Capital Structure as Incentive Rights Lapse and Are Cancelled","url":"https://stock-news.laohu8.com/highlight/detail?id=2618681971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618681971?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:11","pubTimestamp":1773267075,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has reported the cessation of several classes of equity-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-tightens-capital-structure-as-incentive-rights-lapse-and-are-cancelled?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-tightens-capital-structure-as-incentive-rights-lapse-and-are-cancelled?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618716359","title":"Telix Seeks ASX Quotation for New Employee Share Plan Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2618716359","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618716359?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:11","pubTimestamp":1773267064,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has applied to the ASX for quotation of 50,782 new fully...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-seeks-asx-quotation-for-new-employee-share-plan-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-seeks-asx-quotation-for-new-employee-share-plan-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618396777","title":"UBS Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396777?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:05","pubTimestamp":1773183925,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$31.00. Dai covers the Healthcare sector, f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618193237","title":"Why Is Telix Pharmaceuticals Stock Gaining Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618193237","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618193237?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:01","pubTimestamp":1773140460,"startTime":"0","endTime":"0","summary":"Telix Pharma's ProstACT study achieves primary objectives, positioning TLX591-Tx as potential first-line treatment for prostate cancer.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/10/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/10/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51151940/why-is-telix-pharmaceuticals-stock-gaining-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51151940/why-is-telix-pharmaceuticals-stock-gaining-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","BK4139","SMA","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618982263","title":"Telix Says Part 1 of Late-Stage Trial of Prostate Cancer Treatment Achieves Primary Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2618982263","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618982263?lang=en_us&edition=fundamental","pubTime":"2026-03-10 15:52","pubTimestamp":1773129179,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said late Monday that part 1 of a phase 3 trial of TLX591-Tx in patients with metastatic castration resistant prostate cancer achieved its primary objectives.Results of the study showed an acceptable safety and tolerability profile with no new safety signals observed, the company said.Telix also said it has advanced the study into part 2.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU","BK4139","SSI","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":199,"code":"91000000","status":"200"}]}}